Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Alexion RI Facility Gets EU Boost | Contract Pharma

What are you searching for?

Sign in
Breaking News, Trials & Filings

Alexion RI Facility Gets EU Boost

Alexion Pharmaceuticals’s RI facility is near approval as a second source of supply for Soliris.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Alexion Pharmaceuticals’s Rhode Island manufacturing facility (ARIMF) in Smithfield, RI is near approval as a second source of supply for Soliris. The company reported that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a “positive opinion” recommending final approval of the facility by the European Commission, which is expected in early 2010.

Separately, Alexion will meet with the FDA to provide additional available information and to discuss the agency’s request for a limited number of production runs in connection with their pre-approval inspection process.

Since 2006, Alexion has been developing ARIMF to become a second source of supply of Soliris and to manufacture other antibody products. The facility does not yet provide Soliris for commercial use in any market. As a result of the company’s previously described multi-source strategy, Alexion has existing supplies of Soliris sufficient to serve all anticipated clinical and commercial needs, while continuing to source product from its primary provider.

“We are pleased to receive the positive opinion from the CHMP, which would give us the option to use ARIMF as a second source to supply Soliris to European countries following final EU approval,” said Stephen P. Squinto, executive vice president and head of R&D at Alexion. “We now look forward to progressing our discussions and satisfying the requirements of the FDA, which would give us the additional option of using our Rhode Island facility as a second source to serve the U.S. market as well.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters